The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial (REGARD-PGx)

Merck KGaA (EMD Serono) logo

Merck KGaA (EMD Serono)

Status and phase

Completed
Phase 4

Conditions

Relapsing Multiple Sclerosis

Treatments

Other: Blood sampling

Study type

Interventional

Funder types

Industry

Identifiers

NCT01034579
EMR200136_023

Details and patient eligibility

About

This study, REbif® vs Glatiramer acetate in relapsing multiple sclerosis (MS) disease - pharmacogenetic(s) (REGARD-PGx) is a single blood sampling exploratory pharmacogenetic study of the REGARD trial. The aim of this trial is to provide additional data on the factors influencing interferon (IFN) beta response. This is a Phase 4 trial involving subjects who previously participated in the REGARD trial. To address the trial objectives, a single visit follow-up trial will be performed during which a blood sample will be collected.

Enrollment

324 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Was randomized in the REGARD 24735 study
  • Is willing and able to comply with the protocol
  • Has given written informed consent before performing any trial-related activities

Exclusion criteria

  • Is unwilling or unable to participate in the study
  • Is already included in the initial REGARD 24735 PGx sub-study

Trial design

324 participants in 2 patient groups

Rebif® Cohort
Other group
Treatment:
Other: Blood sampling
Copaxone® Cohort
Other group
Treatment:
Other: Blood sampling

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems